Bayer Aktiengesellschaft (BAYRY): Price and Financial Metrics
GET POWR RATINGS... FREE!
BAYRY Stock Price Chart Interactive Chart >
BAYRY Price/Volume Stats
| Current price | $15.73 | 52-week high | $21.05 |
| Prev. close | $15.97 | 52-week low | $11.65 |
| Day low | $15.64 | Volume | 217,500 |
| Day high | $15.78 | Avg. volume | 446,214 |
| 50-day MA | $16.36 | Dividend yield | 2.61% |
| 200-day MA | $15.37 | Market Cap | 58.68B |
Bayer Aktiengesellschaft (BAYRY) Company Bio
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, and self-care solutions in the dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. Bayer Aktiengesellschaft has a collaboration agreement with MD Anderson Cancer Center at the University of Texas to develop cancer treatments; and research collaboration agreements with Haplogen GmbH and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. The company distributes its products through wholesalers, pharmacies, supermarket and drugstore chains, online and other retailers, and hospitals, as well as directly to farmers. It has strategic research alliance with Kyoto University, Sensyne Health plc, and Atomwise Inc. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.
Latest BAYRY News From Around the Web
Below are the latest news stories about Bayer Aktiengesellschaft that investors may wish to consider to help them evaluate BAYRY as an investment opportunity.
Bayer's Cell, Gene Therapies for Parkinson's Disease Enters Human TrialsBayer AG’s (OTC: BAYRY) Parkinson’s disease stem cell therapy has officially landed in the clinic, while another treatment for the neurodegenerative movement disorder is recruiting patients. Bayer’s subsidiary BlueRock Therapeutics’s trial will eventually enroll 10 participants. Patients will have dopamine-producing cells surgically implanted into a part of the brain called the putamen. The trial will primarily examine the safety and tolerability of DA01 cell transplantation a year after the pro |
Novartis (NVS) Posts Positive Data on Kidney Disease CandidateNovartis' (NVS) rare kidney disease candidate meets its primary goal in a phase II study. |
Bayer Buys Two Biotech Firms to Beef Up RadiopharmaceuticalsBayer AG (OTC: BAYRY) will acquire two small biotech companies in a deal that adds an experimental prostate cancer medicine to the German drugmaker's pipeline. Bayer will pay an undisclosed sum for Noria Therapeutics and PSMA Therapeutics, built around radiotherapy research from the Weill Cornell Medical College in NYC. The deal is centered around an actinium-225 labeled prostate-specific membrane antigen (PSMA) small molecule currently in pre-IND studies for prostate cancer. Bayer has its portf |
J&J (JNJ) to Pay $2.5B in Baby Powder Case on Appeal RejectionThe U.S. Supreme Court rejects J&J's (JNJ) appeal against a lower court verdict of $2.1 billion in damages in a litigation related to its talc-based baby powder. |
Bayer to review Roundup's future in U.S. after court setbackBayer (BAYRY) says it will evaluate whether to continue using glyphosate in its Roundup weedkiller in the residential U.S. market after a judge today rejected its plan to settle future claims alleging the herbicide causes cancer.Bayer also says it will abandon attempts at a court-approved solution to address its future... |
BAYRY Price Returns
| 1-mo | -7.63% |
| 3-mo | 1.33% |
| 6-mo | 10.16% |
| 1-year | -16.28% |
| 3-year | -39.91% |
| 5-year | -31.31% |
| YTD | 8.71% |
| 2020 | -24.50% |
| 2019 | 19.17% |
| 2018 | -42.40% |
| 2017 | 21.36% |
| 2016 | -15.03% |
BAYRY Dividends
| Ex-Dividend Date | Type | Payout Amount | Change | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Loading social stream, please wait...